Sorrento Therapeutics Inc. [NASDAQ: SRNE] traded at a low on 01/12/22, posting a -4.06 loss after which it closed the day’ session at $4.49. The company report on January 7, 2022 that Sorrento Therapeutics Announces the Unexpected Death of its Chief Financial Officer.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the unexpected passing of Mr. Najjam Asghar, Chief Financial Officer and Senior Vice President. Mr. Asghar died of apparent natural causes on January 6, 2022.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
“Sorrento is deeply saddened and shocked by the loss of our dear friend and colleague. Our immediate thoughts go to Najjam’s family and friends,” said Dr. Henry Ji, Sorrento’s Chairman and CEO. “We appreciate and thank Najjam for his tremendous contributions to Sorrento and the San Diego life sciences community.”.
The results of the trading session contributed to over 4698855 shares changing hands. Over the past one week, the price volatility of Sorrento Therapeutics Inc. stands at 6.31% while the volatility over the past one month is 6.61%.
The market cap for SRNE stock reached $1.61 billion, with 299.28 million shares outstanding and 276.34 million shares in the current float. Compared to the average trading volume of 5.37M shares, SRNE reached a trading volume of 4698855 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Sorrento Therapeutics Inc. [SRNE]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SRNE shares is $26.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SRNE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley Securities have made an estimate for Sorrento Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 29, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on January 21, 2021, representing the official price target for Sorrento Therapeutics Inc. stock. Previously, the target price had yet another raise from $24 to $30, while H.C. Wainwright kept a Buy rating on SRNE stock.
The Average True Range (ATR) for Sorrento Therapeutics Inc. is set at 0.37, with the Price to Sales ratio for SRNE stock in the period of the last 12 months amounting to 31.44. The Price to Book ratio for the last quarter was 10.20, with the Price to Cash per share for the same quarter was set at 0.45.
How has SRNE stock performed recently?
Sorrento Therapeutics Inc. [SRNE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.05. With this latest performance, SRNE shares dropped by -27.93% in over the last four-week period, additionally sinking by -43.31% over the last 6 months – not to mention a drop of -38.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRNE stock in for the last two-week period is set at 33.33, with the RSI for the last a single of trading hit 31.84, and the three-weeks RSI is set at 34.90 for Sorrento Therapeutics Inc. [SRNE]. The present Moving Average for the last 50 days of trading for this stock 5.75, while it was recorded at 4.58 for the last single week of trading, and 7.43 for the last 200 days.
Sorrento Therapeutics Inc. [SRNE]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sorrento Therapeutics Inc. [SRNE] shares currently have an operating margin of -503.99 and a Gross Margin at +51.68. Sorrento Therapeutics Inc.’s Net Margin is presently recorded at -746.41.
Return on Total Capital for SRNE is now -63.61, given the latest momentum, and Return on Invested Capital for the company is -93.64. Return on Equity for this stock declined to -244.90, with Return on Assets sitting at -49.06. When it comes to the capital structure of this company, Sorrento Therapeutics Inc. [SRNE] has a Total Debt to Total Equity ratio set at 102.57. Additionally, SRNE Total Debt to Total Capital is recorded at 50.63, with Total Debt to Total Assets ending up at 28.29. Long-Term Debt to Equity for the company is recorded at 86.32, with the Long-Term Debt to Total Capital now at 42.61.
Reflecting on the efficiency of the workforce at the company, Sorrento Therapeutics Inc. [SRNE] managed to generate an average of -$594,544 per employee. Receivables Turnover for the company is 2.66 with a Total Asset Turnover recorded at a value of 0.07.Sorrento Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.10.
Earnings analysis for Sorrento Therapeutics Inc. [SRNE]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sorrento Therapeutics Inc. go to 37.00%.
Insider trade positions for Sorrento Therapeutics Inc. [SRNE]
There are presently around $385 million, or 24.40% of SRNE stock, in the hands of institutional investors. The top three institutional holders of SRNE stocks are: BLACKROCK INC. with ownership of 20,867,671, which is approximately 9.152% of the company’s market cap and around 0.60% of the total institutional ownership; VANGUARD GROUP INC, holding 15,506,493 shares of the stock with an approximate value of $69.62 million in SRNE stocks shares; and STATE STREET CORP, currently with $55.17 million in SRNE stock with ownership of nearly 20.082% of the company’s market capitalization.
Positions in Sorrento Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 98 institutional holders increased their position in Sorrento Therapeutics Inc. [NASDAQ:SRNE] by around 11,117,817 shares. Additionally, 72 investors decreased positions by around 3,165,041 shares, while 66 investors held positions by with 71,475,576 shares. The mentioned changes placed institutional holdings at 85,758,434 shares, according to the latest SEC report filing. SRNE stock had 30 new institutional investments in for a total of 614,610 shares, while 18 institutional investors sold positions of 964,094 shares during the same period.